NYSE: HAEHaemonetics Revenue
Haemonetics revenue was $1.36B for the trailing 12 months ending Mar 29, 2025, with 43.5% growth year over year. Quarterly revenue for the quarter (Q1 2025) ending on Mar 29, 2025 was $330.6M, down 5.1% from last quarter. For the last reported fiscal year 2025 ending Mar 29, 2025, HAE annual revenue was $1.4B, with 4% growth year-over-year.
HAE past revenue growth
How has HAE's revenue growth performed historically?
Company
3.95%
Industry
13.53%
Market
20.46%
HAE's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
HAE's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
HAE's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance
HAE revenue history
Current Revenue
$1.4B
Current Earnings
$167.7M
Current Profit Margin
12.3%
HAE's has demonstrated consistent long-term... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance
Be the first to know when HAE announces revenue.
HAE Revenue History By Year
| HAE Yearly Revenue | HAE Revenue | HAE Change | HAE Revenue Growth |
|---|---|---|---|
| 2025-03-29 | $1.36B | $51.77M | +3.95% |
| 2024-03-30 | $1.31B | $140.40M | +12.01% |
| 2023-04-01 | $1.17B | $175.46M | +17.67% |
| 2022-04-02 | $993.20M | $122.73M | +14.10% |
| 2021-04-03 | $870.46M | -$118.02M | -11.94% |
| 2020-03-28 | $988.48M | $20.90M | +2.16% |
| 2019-03-30 | $967.58M | $63.66M | +7.04% |
| 2018-03-31 | $903.92M | $17.81M | +2.01% |
| 2017-04-01 | $886.12M | -$22.72M | -2.50% |
| 2016-04-02 | $908.83M | -$1.54M | -0.17% |
| 2015-03-28 | $910.37M | -$28.14M | -3.00% |
| 2014-03-29 | $938.51M | $46.52M | +5.22% |
| 2013-03-30 | $891.99M | $164.15M | +22.55% |
| 2012-03-31 | $727.84M | $51.15M | +7.56% |
| 2011-04-02 | $676.69M | $31.26M | +4.84% |
| 2010-04-03 | $645.43M | $47.55M | +7.95% |
| 2009-03-28 | $597.88M | $81.44M | +15.77% |
| 2008-03-29 | $516.44M | $66.83M | +14.86% |
| 2007-03-31 | $449.61M | $29.87M | +7.12% |
| 2006-04-01 | $419.73M | $36.14M | +9.42% |
| 2005-04-02 | $383.60M | $19.37M | +5.32% |
| 2004-04-03 | $364.23M | $27.27M | +8.09% |
| 2003-03-29 | $336.96M | $16.99M | +5.31% |
| 2002-03-30 | $319.97M | $26.11M | +8.88% |
| 2001-03-31 | $293.86M | $13.25M | +4.72% |
| 2000-04-01 | $280.61M | -$3.90M | -1.37% |
| 1999-04-03 | $284.51M | -$1.25M | -0.44% |
| 1998-03-28 | $285.76M | -$17.25M | -5.69% |
| 1997-03-29 | $303.01M | $26.54M | +9.60% |
| 1996-03-30 | $276.47M | $14.05M | +5.36% |
| 1995-04-01 | $262.42M | N/A | N/A |
Haemonetics Revenue FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.